Sign in
Enrolling by invitationNo phase

Studying vaginal bacteria in women with and without vaginal conditions

Collects vaginal swabs to study bacteria in women with common vaginal and urinary infections.

Key facts

Who runs it
Vaginal Biome Science
Where
Alexandria, Bethesda, Bryn Mawr, Corvallis, Easton, Fullerton, Henderson, Honolulu, Kenmore, Los Angeles, Mayfield Heights, New York, Oklahoma City, Pasadena, Portland, Shenandoah, Tulsa, Virginia Beach, and Winston-Salem, United StatesSee the 20 sitesAlso in 1 other country, 1 site
Trial code
Registry title
Vaginal Ecosystem and Network in the United States Study
Status
Enrolling by invitation
People taking part
3,250 people, planned
Started
16 May 2024
Expected to end
15 May 2028
Type of study
Observational, 13 groups
Treatments tested
  • Vaginal Swab Collection
Record updated
1 July 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for healthy women, and women with certain gynecological conditions or cancer, to give a vaginal swab for microbiome testing.

Age
18 to 89 years
Sex
Women only
Disease stage
Healthy women (before, during or after menopause), or women with bacterial vaginosis, yeast infection, urinary tract infection, genitourinary syndrome of menopause, lichen sclerosus or planus, vulvodynia, endometriosis, Ureaplasma, desquamative inflammatory vaginitis, or cancer (stages 1-4).
Earlier treatment
For women with cancer, some groups need anti-estrogen therapy or vaginal estrogen, prasterone or DHEA for at least 90 days; other groups must not have had it. Systemic hormone replacement therapy is not allowed in some cancer groups.

Main reasons for not taking part

  • Pregnant
  • Trying to conceive (for example IVF or IUI)

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Healthy cis-gender women between ages 18 and 89

Who cannot take part

  • Pregnant or trying to conceive (i.e. IVF, IUI)

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 89 years old?

Where in United States

Also in 1 other country, 1 site

  • Empowered Midwifery and Wellness LLCAlexandria, United StatesEnrolling by invitation
  • Rachel Rubin MD PLLCBethesda, United StatesEnrolling by invitation
  • Center for Pelvic MedicineBryn Mawr, United StatesEnrolling by invitation
  • Center of the HealthCorvallis, United StatesEnrolling by invitation
  • Dr. Christina Enzmann at Easton Advanced Aesthetics and Regenerative MedicineEaston, United StatesEnrolling by invitation
  • Women's Pelvic Health CenterFullerton, United StatesEnrolling by invitation
  • Xena HealthHenderson, United StatesEnrolling by invitation
  • Healthy Mothers, Healthy Babies Coalition of HawaiiHonolulu, United StatesEnrolling by invitation
  • Empire OBGYNKenmore, United StatesEnrolling by invitation
  • Claris HealthLos Angeles, United StatesEnrolling by invitation
  • University of California Los Angeles Department of Radiation OncologyLos Angeles, United StatesEnrolling by invitation
  • UH HospitalsMayfield Heights, United StatesEnrolling by invitation
  • Gary H Goldman, MDNew York, United StatesEnrolling by invitation
  • Northwest Obstetrics and GynecologyOklahoma City, United StatesEnrolling by invitation
  • Pelvic Pain RehabPasadena, United StatesEnrolling by invitation
  • Amber Wellness GroupPortland, United StatesEnrolling by invitation
  • North Houston Gynecologic Oncology Surgeons, PLLCShenandoah, United StatesEnrolling by invitation
  • Haven Center for Sexual Medicine & Vulvovaginal DisordersTulsa, United StatesEnrolling by invitation
  • Hello ClimaxVirginia Beach, United StatesEnrolling by invitation
  • Camel City Women's WellnessWinston-Salem, United StatesEnrolling by invitation

About the trial

What the trial wants to find out

The central premise of this study is that the intricate balance and diversity of the vaginal microbiome plays a pivotal role in the onset, progression, and severity of various gynecological conditions. Specifically, the research aims to investigate how imbalances in microbial communities, such as the overgrowth of pathogenic bacteria or the depletion of beneficial ones, are linked to conditions like Bacterial Vaginosis, Candidiasis, Urinary Tract Infections, Vaginal Atrophy, and others. By employing PCR testing and the outcomes of next-generation sequencing (NGS) of the microbiome, the study seeks to identify distinct microbial profiles and patterns that are characteristic of each condition. This nuanced understanding is expected to lead to more accurate and early diagnosis, facilitating personalized and effective treatment strategies that go beyond the conventional, often indiscriminate use of antibiotics.

The 13 groups in the trial

  • Premenopausal Healthy

    Treatment: Vaginal Swab Collection

  • Perimenopausal Healthy

    Treatment: Vaginal Swab Collection

  • Postmenopausal Healthy

    Treatment: Vaginal Swab Collection

  • Bacterial Vaginosis

    Treatment: Vaginal Swab Collection

  • Candidiasis

    Yeast Infections

    Treatment: Vaginal Swab Collection

  • Urinary Tract Infection

    Premenopausal and Postmenopausal Women

    Treatment: Vaginal Swab Collection

  • Genitourinary Syndrome of Menopause

    Vaginal Atrophy

    Treatment: Vaginal Swab Collection

  • Lichen Sclerosus/Planus

    Treatment: Vaginal Swab Collection

  • Vulvodynia

    Treatment: Vaginal Swab Collection

  • Endometriosis

    Treatment: Vaginal Swab Collection

  • Ureaplasma

    Treatment: Vaginal Swab Collection

  • Desquamative Inflammatory Vaginitis (DIV)

    Treatment: Vaginal Swab Collection

  • Cancer

    Group 1: Breast cancer patients diagnosed at stages 1-3, post-menopausal (due to surgical, chemical reasons, or age-related natural processes), and currently receiving anti-estrogen treatment for a minimum of 90 days. Group 2: Breast cancer patients diagnosed at stages 1-3, pre-menopausal, and undergoing anti-estrogen endocrine therapy for at least 90 days. Group 3: Participants diagnosed with any type of cancer at stages 1-3, not receiving anti-estrogen therapy, but have been using vaginal estrogen, prasterone, or DHEA for 90 days or more. Should not be on systemic hormone replacement therapy (estrogen with or without progesterone). Group 4: Diagnosed with any type of cancer at stages 1-3, and should not be receiving any anti-estrogen therapy or using vaginal estrogen, prasterone, or DHEA. These individuals must not be on systemic hormone replacement therapy. Group 5: Participants diagnosed at stage 4

    Treatment: Vaginal Swab Collection

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Comprehensive Registry and PCR Analysis of the Vaginal Microbiome in Women: Data Collection in Healthy and Diseased States
Plain-language title
Studying vaginal bacteria in women with and without vaginal conditionsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06472765, who can take part
Record updated
1 July 2025